Kornimate/medical-research-clean huggingface dataset:
cognitive functioning related to job tenure among patients with schizophrenia

Conditions: Schizophrenia

Summary: the aim of this research is to explore which cognitive function would affect the job tenure among people with schizophrenia. the investigators plan to recruit 60 people diagnosed with schizophrenia and divide into two groups, employment and unemployment. the investigators will use several cognitive function tests to collect their cognitive functions and panss to evaluate their psychotic symptoms. and then the investigators will compare and analysis the data through statistic software. finally, the investigators will have the answer about if cognitive functions would affect the job tenure among people with schizophrenia. and the investigators hope that we could get the predict factor of cognitive function to predict the successful employment in future.


Eligibility criteria:
inclusion criteria: * schizophrenia, 18\~44y/o exclusion criteria: * substance abuse
randomized study of weekly erythropoietin dosing in preterm infants

Conditions: Preterm Infants

Summary: preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (epo) has been shown to decrease transfusion requirements. dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. the investigators assessed weekly epo dosing in preterm infants compared to standard three times weekly dosing.

erythropoietin (epo) increases and maintains hematocrit using once weekly dosing in adults with anemia due to end stage renal disease. epo is used in preterm infants to treat the anemia of prematurity, but has not been studied using once weekly dosing. we compared reticulocyte responses of once weekly epo dosing with thrice weekly dosing in preterm infants. infants ≤1,500 grams and ≥7 days of age were randomized to once weekly epo, 1,200 units/kg/dose, or thrice weekly epo, 400 units/kg/dose, subcutaneously for 4 weeks, along with iron and vitamin supplementation. complete blood counts, absolute reticulocyte counts (arc), transfusions, phlebotomy losses, and adverse events were recorded.

Eligibility criteria:
inclusion criteria: * \< or = 1,500 grams * \< or = 32 weeks gestation * \> or = 7 days of age * informed consent obtained exclusion criteria: * hemolytic disease * hypertension * seizures * thromboses * major malformation

Keywords: anemia transfusions erythropoiesis neonate preterm
alucent vessel restoration system for avf

Conditions: AV Fistula

Summary: feasibility of the vessel restoration system for avf

a study of the safety and feasibility of the vessel restoration system for avf to promote the physiologic and functional maturation of a brachiocephalic end-to-side arteriovenous fistulas (avf) in patients with chronic kidney disease stage v (pre-dialysis): activate avf

Eligibility criteria:
inclusion criteria: * 18 years of age and can provide informed consent * use birth control * chronic kidney disease exclusion criteria: * receiving hemodialysis * pregnant, breastfeeding, planning to become pregnant * receiving immunosuppressants * has "long covid"
celagace™ orarinse solution for treatment of candidiasis

Conditions: Candidiasis, Oral

Summary: celagace™ orarinse (silver citrate complex and acemannan) solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.

celagace™ contains two active ingredients, a silver citrate complex salt (0.01mg/ml) that has demonstrated laboratory effectiveness against yeast organisms and acemannan (4.0mg/ml), a purified extract isolated from the inner leaf gel of the aloe vera plant that has been used as a key ingredient in other oral care products. patients will swish and spit the product 4 times daily (after meals and at bedtime) for 14 days. following an initial office visit, patients will be evaluated on days 7 and 14 to determine response to the product.

Eligibility criteria:
inclusion criteria: * radiation induced oral mucositis with resulting candidiasis * chemotherapy induced oral mucositis with resulting candidiasis * oral mucositis due to being immunocompromised with resulting candidiasis * stomatitis due to other causes with resulting candidiasis * currently have mild to moderate mucositis exclusion criteria: patient: * under the age of 18 * pregnant or breastfeeding * inability to use an oral rinse * hypersensitivity to aloe vera and/or silver * whose candida rinse culture was performed greater than 10 days prior to study entry. * has any sort of removable dental appliance * with previous or current history of any cancer of the oral cavity * who received therapy for candidiasis within the past 30 days * who used antifungal medication in the last 30 days * who has severe to life threatening oral muositis (grade iii-iv) oral mucositis * with impaired renal or hepatic function * receiving high dose chemotherapy and total body irradiation in preparation for hemopoietic stem cell transplant (hsct) or concomitant use of kepivance® (palifermin or rhkgf)

Keywords: oral candidiasis, thrush, oral moniliasis
safety and efficacy of liposomal latanoprost in ocular hypertension

Conditions: Ocular Hypertension

Summary: aim: evaluation of a single subconjunctival injection of liposomal eggpc formulation of latanoprost in treating glaucoma. hypothesis: the investigators have already evaluated carrier stability, drug partitioning, in vitro drug release, tolerance, and efficacy of latanoprost-incorporated eggpc liposomes upon subconjunctival administration in both rabbit and monkey eyes. therefore, the investigators hypothesize that this would be safe and efficacious in humans as well. methodology: a pilot study to assess a liposome formulation containing latanoprost. the investigators will recruit 6 study subjects with eyes that have raised iop, for subconjunctival injection of this liposome formulation. the recruited eye will be injected and monitored for inflammation, toxicity and pain as primary end-points. monitoring of the eye will be for the first 24 hours post-injection, week 2, months 1, 2 and 3 thereafter. importance: if proven safe, this method of drug delivery could potentially be used for treatment of raised intraocular pressures in blinding conditions such as glaucoma.

the number of recorded adverse events and intolerance to the subconjunctival injection procedure by the participants during the study period was used as a measure of safety.

Eligibility criteria:
inclusion criteria: glaucoma patients who have eyes with raised iop (baseline iop \>21 mmhg) due to end-stage glaucoma with a poor visual prognosis. exclusion criteria: 1. active or recent eye infection, endophthalmitis 2. known hypersensitivity to latanoprost 3. only eye 4. previous glaucoma filtration surgeries or trabeculectomy 5. intraocular pressure less than 12mmhg. 6. inability to give informed consent. 7. inability to safely administer a subconjunctival injection 8. uncontrolled systemic hypertension, cva or tia within the previous month. 9. pregnancy -

Keywords: glaucoma raised intraocular pressure
computerized brief intervention vs. delayed computerized brief intervention

Conditions: Drug Abuse

Summary: the purpose of the study is to determine whether a computerized brief intervention for moderate risk drug use among adult primary care patients is more effective than providing such patients with a substance abuse assessment alone.

the study will enroll 80 adult primary care patients who have moderate risk drug use. eligible participants (n = 80) will be randomly assigned to immediately receive a computerized brief intervention focused on drug use or to receive the same computerized brief intervention at 3-month follow-up. all participants will be assessed at three time points: baseline, and at 3 and 6 month follow-ups.

Eligibility criteria:
inclusion criteria: * (1) minimum 18 years of age * (2) primary care or dental patients at the participating clinics * (3) score between 4 and 26 (moderate-risk) for illicit drug and/or nonmedical use of prescription drugs on any of the single item drug use risk scores of the assist. exclusion criteria: * (1) score in the high-risk range on the assist for any drug (except tobacco) or alcohol use (i.e., assist score \> 26) * (2) no reported drug use within the past 3 months * (3) drug abuse treatment within the past 12 months * (4) a bi at the clinic with the behavioral health counselor within the past month * (5) prior enrollment in the parent study; * (6) plans to move out of new mexico in the next 6 months

Keywords: brief intervention computerized brief intervention
a study of ono-2020 in patients with agitation associated with alzheimer's disease dementia

Conditions: Agitation Associated With Alzheimer's Disease Dementia

Summary: to evaluate the efficacy and safety of ono-2020 in patients with agitation associated with alzheimer's disease dementia in japan.


Eligibility criteria:
inclusion criteria: * diagnosis of probable ad according to the diagnostic criteria for ad dementia (nia-aa 2011) * mini-mental state examination (mmse) score ≥ 5 to ≤ 22 at the start of the treatment period * symptoms of agitation defined by the ipa from at least 14 days before the start of the screening period * neuropsychiatric inventory-nursing home version (npi-nh) agitation/aggression domain (npi-nh-a/a) score ≥ 4 at the start of the treatment period. * patients who can participate in the study under hospitalization from 21 days before the start of the treatment period to throughout the treatment period exclusion criteria: * diagnosis of dementia not due to ad or any other disorder with memory impairment, such as mixed dementia, vascular dementia, lewy body dementia, dementia associated with parkinson's disease, frontotemporal dementia, drug-induced dementia, dementia associated with human immunodeficiency virus (hiv) infection, traumatic brain injury, normal pressure hydrocephalus, or other non-ad dementia * any mri or ct scan of the brain performed after the onset of dementia with findings consistent with clinically relevant cns disease other than ad, such as vascular changes (eg, cortical cerebral infarction, multiple cerebral infarctions), space-occupying lesions (eg, tumors), or any other major structural brain disease * delirium within 30 days before the start of the screening period or a history of delirium * at risk of suicide according to the columbia-suicide severity rating scale (c-ssrs) (answers "yes" to question 4 or 5 of the suicidal ideation section of the c-ssrs) or any suicide attempt within 6 months before the start of the screening period, or at serious risk of suicide in the opinion of the investigator or subinvestigator * prior or current treatment with anti-amyloid beta antibodies
transversus abdominis plane block and inguinal hernia repair

Conditions: Inguinal Hernia; Abdominal Wall Muscles; Regional Anesthesia; Postoperative Pain

Summary: this prospective, randomized, double blinded, placebo-controlled study is designed to evaluate the postoperative analgesic efficacy of the ultrasound-guided transversus abdominis plane block with ropivacaine 0,75 %, in patients undergoing unilateral inguinal hernia repair with a mesh under general anaesthesia, and how the efficiency of early postoperative analgesia achieved correlates with the risk of developing a chronic pain state, a not uncommon condition after this type of surgery.


Eligibility criteria:
inclusion criteria: asa i-iii patients undergoing inguinal hernia repair with a mesh age between 18 and 75 years old ability to read and write greek - exclusion criteria: * inability to consent to the study * bmi \>40kg/m2 * skin infection at the puncture site * contraindication to mono-amide local anaesthetics, paracetamol, nsaid's (parecoxib) * preoperative use of opioids or nsaid's for chronic pain conditions

Keywords: transversus abdominis plane block inguinal hernia repair acute postoperative pain neuropathic pain
fdg-pet scan response guided chemotherapy strategy for advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the usual response to chemotherapy is decided through the image change by computed tomography (ct), which is taken at least 6-9 weeks. in order to predict the response to chemotherapy earlier, patients received fdg-pet scan at the first cycle of chemotherapy. chemotherapy was guided by the metabolic response by fdg-pet scan.

prospective, open-label, randomized phase ii, single institution trial that compared chemotherapy guided by traditional evaluation based on recist versus chemotherapy guided by fdg-pet (metabolic) response.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed non-small cell carcinoma. 2. stage iiib (wet) or iv advanced nsclc. 3. no evidence of prior malignancies for 3 years except treated basal cell or squamous cell carcinoma of skin and carcinoma in situ of uterine cervix. 4. measurable disease by recist criteria. 5. adequate organ function as follows. * seum ast/alt \< 2.5 x upper normal limit (unl) (if hepatic metastasis \< 5 x unl) * total bilirubin \< 1.5 x unl * serum creatinine \< 1.5 mg/dl * absolute neutrophil count \> 1500/ul * platelet \> 100,000/ul * hemoglobin \> 9.0 g/dl 6. ecog performance status 0-1 7 age \> 18 8. if previously treated with major surgery, it should be over at least 4 weeks. and if previously treated with radiotherapy, it should be over at least 2 weeks. 9. written consent exclusion criteria: 1. previous chemotherapy. 2. symptomatic brain metastasis. 3. concurrent severe medical illness. 4. pregnancy and lactation. 5. if there are findings which may increase risk with chemotherapy or inhibit to analyze the result of clinical trial. * uncontrolled diabetes mellitus.

Keywords: non small cell lung cancer fdg pet
intervention to decrease overtreatment of patients with low-risk thyroid cancer

Conditions: Thyroid Cancer

Summary: the study will include 50 patients newly diagnosed with low-risk thyroid cancer ranging from 18-80 years of age. after scheduling their surgeon visit, the investigators will enroll patients and measure their intended treatment choice, baseline awareness of the three treatment options, expected outcomes, self-efficacy, and activation. the participants will then be randomized 1:1 and deliver the cquple intervention to the intervention group. the control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit. the study team will repeat all measures prior to the surgical consult and after the surgical consult. the study team will record the patients' actual treatment choice after the consult.


Eligibility criteria:
inclusion criteria: * age 18 to 80 years * low risk papillary thyroid cancer or highly suspicious for cancer * low risk papillary thyroid cancer * ct1-2: tumor size 4 cm or smaller and limited to the thyroid on ultrasound * cn0: no evidence of lymph node metastasis on ultrasound * cm0: no evidence of distant metastasis on imaging * highly suspicious for cancer * cytology meeting bethesda v or bethesday iii or iv with molecular testing indicating a 70% risk of greater of thyroid cancer * nodule size 4 cm and smaller * limited to the thyroid on ultrasound * no evidence of suspicious lymph nodes * no evidence of thyroid cancer outside of the neck * referred for surgical consultation. exclusion criteria: * history of previous thyroid cancer or thyroid surgery and parathyroid surgery * non-english speaking * deaf subject selection (for surgeons) surgeon inclusion criteria * performs at least one thyroid surgery annually on adults * credentialed at michigan medicine surgeon exclusion criteria * none
evaluation of the arthritis basics for change (abcs) self management program

Conditions: Arthritis

Summary: while there are a variety of arthritis education materials available, the evidence-base on most of them is slim, so it i impossible to know what benefits they may have for the people who participate. the purpose of this project is to evaluate the effectiveness of the mail-delivered self-management education program, arthritis basics for change (abcs) with an emphasis on changes in knowledge, beliefs, behavior, self efficacy and health outcomes, and to evaluate the appropriateness, usefulness, and readibility of the program. this project will assist cdc's arthritis program in determining the usefulness of the abcs program for helping people with arthritis improve their quality of life.


Eligibility criteria:
inclusion criteria: adults with arthritis exclusion criteria: -

Keywords: arthritis self management patient education
repeated open application test (roat) study with hydroperoxides of linalool

Conditions: Allergic Contact Dermatitis

Summary: linalool is currently one of the most used fragrance substances in cosmetic and household products. previous studies report a high prevalence (5.9-11.7%) of contact allergy to hydroperoxides of linalool (lin-ooh)1.0% in pet. among patch tested patients. the optimal test concentration of lin-ooh in patch tests is not known and requires further investigation. it is of great importance to establish the optimal test concentration and elicitation threshold of lin-ooh to improve diagnosis and prevent development of allergic contact dermatitis (acd). we want to mimic real-life exposure to lin-ooh, by conducting a roat (repeated open application test) study, on 40 adult participants (20 patients with confirmed contact allergy to lin-ooh, and 20 healthy participants) to low doses of lin-ooh using a simulated "perfume", during a maximum of 21 days of exposure. with this knowledge, we aim to: 1. establish the optimal patch test concentration to diagnose acd to lin-ooh 2. in case of confirmed contact allergy, examine the threshold value for the development of acd upon daily exposure to a simulated leave-on cosmetic product


Eligibility criteria:
allergic participants: 1. inclusion criteria * positive (at least one reading) or doubtful patch test (at least two readings) result to hydroperoxides of linalool within the last ten years * aged 18 years or older * received written and verbal information of the study * signed written consent form 2. exclusion criteria * active eczema in test areas (volar forearms) * pregnancy or breast feeding * treatment with topical corticosteroids or other immune suppressants on/near test areas within two weeks prior to study start * systemic immune-suppressant treatment within seven days prior to study start * uv exposure of test areas within three weeks prior to study start * unable to cooperate or communicate with the investigators healthy controls: 1. inclusion criteria * aged 18 years or older * received written and verbal information of the study * signed written consent form 2. exclusion criteria * known or possible contact allergy to hydroperoxides of linalool * known contact allergy to other fragrance allergens * active eczema or other known relevant skin diseases * pregnancy or breast feeding * treatment with topical corticosteroids or other immune suppressants on/near test areas within four weeks prior to study start. * systemic immune-suppressant treatment within four weeks prior to study start. * uv exposure of test areas within three weeks prior to study start. * participation in other clinical studies within four weeks prior to study start. * unable to cooperate or communicate with the investigators.
acamprosate in youth with fragile x syndrome

Conditions: Fragile X Syndrome; Autism Spectrum Disorders

Summary: fragile x syndrome (fxs) is the most common inherited form of developmental disability. fxs is inherited from the carrier parent, most often the mothers. fxs is associated with severe interfering behavioral symptoms which include anxiety related symptoms, attention deficit hyperactivity, and aggressive behaviors. approximately 25-33% of individuals with fxs also meet criteria for autistic disorder. the hypothesis of this study is that treatment with acamprosate will reduce inattention/hyperactivity, language impairment, irritability, social deficits, and cognitive delay in youth with fxs. the purpose of this study is to investigate the effectiveness and tolerability of acamprosate in youth with fragile x syndrome and to assess the potential psychophysiological differences between fxs and autism spectrum disorders.


Eligibility criteria:
inclusion criteria: * male and female outpatients between the ages of 5 and 17 years. * confirmed diagnosis of fragile x syndrome based upon genetic testing. * stable dosing of all psychotropic medications for at least 2 weeks prior to baseline. * subjects with a stable seizure disorder or history of only childhood febrile seizures will be included. * clinical global impression-severity score of 4 (moderately ill) or greater. * must be in good physical health. * subjects of child bearing age of both genders will be required to utilize birth control as applicable. exclusion criteria: * diagnosis of schizophrenia, another psychotic disorder, bipolar disorder or alcohol or other substance abuse based on diagnostic and statistical manual fourth edition-text revised (dsm-iv-tr). * a significant medical condition such as heart, liver, renal or pulmonary disease or unstable seizure disorder. * females with a positive urine pregnancy test * creatinine clearance of less than 30. * concomitant use of another glutamatergic agent (memantine,riluzole, d-cycloserine, amantadine topiramate, gabapentin, among others. * evidence of hypersensitivity to acamprosate or potentially serious adverse effect. * subjects who, in the opinion of the investigator, are unsuitable in any other way to participate in this study including being unable to comply with the requirements of the study for any reason.

Keywords: fragile x syndrome acamprosate
a real-world study of 650nm low-intensity single-wavelength red light for children and adolescents

Conditions: Myopia

Summary: to evaluate the efficacy and safety of 650nm low-level red-light irradiation for myopia control and prevention in children under less restrictive conditions than randomized controlled trials. participants included children(aged 7 to 18 years, spherical equivalent error of 0.5d or below) who are already myopic at recruitment, and those who are of emmetropia or low hyperopia.

this multicenter real world study will be conducted in at least 100 hospitals: beijing tongren hospital will be the initiator of the study, other hospitals such as the capital institute of pediatrics will serve as sub-centers. the whole study will last for three years.the investigators will perform data analysis at 6 months follow-up, one-year follow-up, and two-year follow-up. participants who used 650 nm low-level red-light would be recruited. this kind of intervention will be integrated into a headworn device. this device could be used for treatment of myopia or amblyopia, and is safe for the eyes and has been verified by the chinese market supervision and administration department.

Eligibility criteria:
inclusion criteria: 1. children aged 7 to 18 years 2. the cycloplegic spherical equivalent error (ser) is +0.5d or less in both eyes 3. astigmatism of 2.5 d or less (≤2.5d) 4. willing to participate in the study and sign the informed consent form exclusion criteria: 1. including but not limited to the following eye diseases: strabismus, amblyopia, ocular tumors, glaucoma/macular disease and other fundus diseases (including heredity), keratitis, eye trauma, uveitis 2. including but not limited to the following systemic diseases: epilepsy, tumor, heart disease, asthma, systemic immune diseases, infectious diseases 3. mental diseases 4. similar interventions have been used in the past year 5. allergic to cycloplegic agents or to red light 6. the 650nm red light intervention was not suitable for the condition evaluated by the researchers 7. are currently using atropine or similar drugs, or have stopped using them for less than 1 month